Seven Fleet Capital Management LP Has $2.80 Million Position in Taysha Gene Therapies, Inc. $TSHA

Seven Fleet Capital Management LP lifted its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 274.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 625,708 shares of the company’s stock after acquiring an additional 458,485 shares during the period. Taysha Gene Therapies comprises about 0.9% of Seven Fleet Capital Management LP’s holdings, making the stock its 25th biggest position. Seven Fleet Capital Management LP’s holdings in Taysha Gene Therapies were worth $2,797,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Intech Investment Management LLC increased its stake in Taysha Gene Therapies by 3.6% during the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock valued at $391,000 after acquiring an additional 2,443 shares during the period. Chicago Partners Investment Group LLC raised its holdings in Taysha Gene Therapies by 1.5% in the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after acquiring an additional 2,504 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock worth $73,000 after acquiring an additional 2,765 shares during the period. Virtus Investment Advisers LLC lifted its position in shares of Taysha Gene Therapies by 7.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after acquiring an additional 3,008 shares during the period. Finally, Principal Financial Group Inc. lifted its position in shares of Taysha Gene Therapies by 26.2% in the 1st quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock worth $72,000 after acquiring an additional 3,362 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TSHA. The Goldman Sachs Group boosted their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Bank of America lifted their price target on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Citizens Jmp reissued a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Finally, Canaccord Genuity Group increased their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.77.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. The trade was a 17.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Stock Down 0.3%

NASDAQ TSHA opened at $5.86 on Friday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The stock’s 50 day moving average is $6.00 and its two-hundred day moving average is $5.38. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -15.42 and a beta of 1.17. Taysha Gene Therapies, Inc. has a 1-year low of $2.54 and a 1-year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Equities analysts forecast that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.